# Gennao Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gennao-bio

- Industry: Biotechnology
- Headquarters: New Haven, US
- Website: www.gennao.com
- Total disclosed funding: $41M
- Latest round: Series A (Dec 22, 2021)
- Investors on record: 4

## About

Based in the US, Gennao Bio, Inc. operates as a biotechnology firm focused on developing innovative solutions for muscle diseases, particularly Duchenne muscular dystrophy, utilizing advanced gene monoclonal antibody technology.Founded in 2020 and headquartered in New Haven, US, Gennao Bio, Inc. specializes in biotechnology solutions. The company has engaged in three deals, with its most recent Series A funding round occurring on December 22, 2021. The financing, amounting to USD 1.0 mn, was led by CureDuchenne Ventures. The founders, Bruce T. and Elias Quijano, have backgrounds that contribute to the firm’s direction, although further details on their previous ventures remain unspecified.Gennao specializes in innovative technology solutions designed to enhance business efficiency and streamline operations. Their primary offerings include advanced software platforms and applications that cater to various industries, focusing on data analytics, workflow automation, and customer relationship management. These products address common pain points such as data silos, inefficient processes, and the need for real-time insights, enabling businesses to make informed decisions and improve productivity. Gennao serves a diverse client base ranging from small to medium-sized enterprises to larger corporations across healthcare, finance, and retail sectors, marketed in North America, Europe, and select markets in Asia.Gennao generates revenue through a structured model that includes subscription services and direct sales of its software solutions. Clients typically engage in annual or multi-year contracts, providing access to Gennao's complete suite of offerings. The company's flagship products, including its data analytics platform and customer relationship management tools, are tailored to improve user engagement and operational efficiency. Pricing plans cater to varied business sizes, ensuring flexibility and accessibility for different market segments, with revenue transactions processed directly between Gennao and its clients to foster long-term partnerships.In December 2021, Gennao Bio, Inc. raised USD 1.0 mn in Series A financing, led by CureDuchenne Ventures. The funding will be utilized to apply their gene monoclonal antibody (GMAB) platform technology specifically to Duchenne muscular dystrophy (DMD) and other rare muscle diseases. The company plans to expand its product offerings and reach new markets, capitalizing on the advancements made possible by the recent investment.

## Funding rounds

- Series A, Dec 22, 2021, $1M — CureDuchenne Ventures
- Series A, May 10, 2021, $40M — OrbiMed Advisors, Surveyor Capital, Logos Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Surveyor Capital — Series A
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series A
- CureDuchenne Ventures (https://capitalatlas.ai/funds/cureduchenne-ventures) — Series A